Cardiovascular diseases (CVDs) represent a significant global health burden, necessitating early and accurate detection for timely intervention and improved patient outcomes. This article  explores the development of nano-enabled biosensors as a promising approach for the early detection of CVDs. It provides a comprehensive overview of the field, including a literature review, fundamental principles, design considerations, and recent advancements.
The article delves into the roles and clinical applications of various cardiovascular disease biomarkers, such as cardiac troponins, natriuretic peptides, C-reactive protein, and lipid profiles. It then examines the integration of nanomaterials, including nanoparticles, carbon nanomaterials, and nanocomposites, into biosensing platforms to enhance sensitivity, selectivity, and overall performance.
Additionally, the document discusses nano-enabled biosensor platforms, such as electrochemical, optical, mechanical, and microfluidic systems, as well as multiplexed and multimodal sensing approaches. It addresses design considerations, challenges, fabrication strategies, and characterization techniques for these biosensors.
Furthermore, the article explores regulatory considerations, commercialization challenges, and future perspectives, including the integration of artificial intelligence, wearable biosensors, and theranostic applications. By leveraging the unique properties of nanomaterials, these advanced biosensors hold great promise for improving early CVD detection, enabling personalized treatment strategies, and ultimately enhancing patient care and outcomes.
Additionally, the document discusses nano-enabled biosensor platforms, such as electrochemical, optical, mechanical, and microfluidic systems, as well as multiplexed and multimodal sensing approaches. It addresses design considerations, challenges, fabrication strategies, and characterization techniques for these biosensors.Furthermore, the article explores regulatory considerations, commercialization challenges, and future perspectives, including the integration of artificial intelligence, wearable biosensors, and theranostic applications. By leveraging the unique properties of nanomaterials, these advanced biosensors hold great promise for improving early CVD detection, enabling personalized treatment strategies, and ultimately enhancing patient care and outcomes.

Keywords: Cardiovascular diseases, biosensors, nanomaterials, early detection, biomarkers, nanoparticles, carbon nanomaterials, multimodal sensing, multiplexing, wearable biosensors, artificial intelligence, commercialization, regulatory considerations

🔒 This is a subscription article

Full text is available to subscribers and institutional members. Please choose an option below to access it.

Cardiovascular diseases (CVDs) represent a significant global health burden, necessitating early and accurate detection for timely intervention and improved patient outcomes. This article  explores the development of nano-enabled biosensors as a promising approach for the early detection of CVDs. It provides a comprehensive overview of the field, including a literature review, fundamental principles, design considerations, and recent advancements.
The article delves into the roles and clinical applications of various cardiovascular disease biomarkers, such as cardiac troponins, natriuretic peptides, C-reactive protein, and lipid profiles. It then examines the integration of nanomaterials, including nanoparticles, carbon nanomaterials, and nanocomposites, into biosensing platforms to enhance sensitivity, selectivity, and overall performance.
Additionally, the document discusses nano-enabled biosensor platforms, such as electrochemical, optical, mechanical, and microfluidic systems, as well as multiplexed and multimodal sensing approaches. It addresses design considerations, challenges, fabrication strategies, and characterization techniques for these biosensors.
Furthermore, the article explores regulatory considerations, commercialization challenges, and future perspectives, including the integration of artificial intelligence, wearable biosensors, and theranostic applications. By leveraging the unique properties of nanomaterials, these advanced biosensors hold great promise for improving early CVD detection, enabling personalized treatment strategies, and ultimately enhancing patient care and outcomes.
Additionally, the document discusses nano-enabled biosensor platforms, such as electrochemical, optical, mechanical, and microfluidic systems, as well as multiplexed and multimodal sensing approaches. It addresses design considerations, challenges, fabrication strategies, and characterization techniques for these biosensors.Furthermore, the article explores regulatory considerations, commercialization challenges, and future perspectives, including the integration of artificial intelligence, wearable biosensors, and theranostic applications. By leveraging the unique properties of nanomaterials, these advanced biosensors hold great promise for improving early CVD detection, enabling personalized treatment strategies, and ultimately enhancing patient care and outcomes.

Keywords: Cardiovascular diseases, biosensors, nanomaterials, early detection, biomarkers, nanoparticles, carbon nanomaterials, multimodal sensing, multiplexing, wearable biosensors, artificial intelligence, commercialization, regulatory considerations

🔒 This is a subscription article

Full text is available to subscribers and institutional members. Please choose an option below to access it.